Bruker 2025 Q2 Earnings Misses Targets with Net Income Down 44.7%

Bruker (BRKR) reported its fiscal 2025 Q2 earnings on Aug 07th, 2025. The company missed revenue expectations and saw a sharp decline in net income. In response, it cut its full-year revenue and earnings guidance for 2025, citing ongoing pressure in key markets and currency headwinds.

Revenue

Bruker's total revenue fell slightly by 0.4% to $797.40 million in 2025 Q2, compared to $800.70 million in the same period last year. The Bruker Scientific Instruments (BSI) segment accounted for the largest share, with $733.20 million in revenue, while Bruker BioSpin generated $195.30 million. The Bruker CALID division reported $285.80 million, and Bruker Nano contributed $252.10 million. The BEST segment added $66.30 million, while eliminations reduced the total by $2.10 million. Collectively, these figures reflect a modest decline in overall revenue, with mixed performance across the company’s business units.

Earnings/Net Income

Despite maintaining the same EPS of $0.05 in 2025 Q2 as in 2024 Q2, Bruker’s net income dropped to $4.20 million from $7.60 million in the prior year, representing a 44.7% decline. This significant reduction in net income signals a challenging earnings performance for the quarter.

Price Action

Following the earnings release, Bruker’s stock price saw a sharp decline, falling 4.16% during the latest trading day and 25.03% over the past full trading week. The month-to-date loss was even steeper, at 25.71%. The stock traded as low as $32.27 in mid-day trading on Monday and closed at $33.45.

Post Earnings Price Action Review

The post-earnings price action for Bruker was underwhelming, with a -6.71% return for investors who bought the stock after it beat revenue expectations and held for 30 days. This significantly underperformed the benchmark return of 84.77%. The strategy showed a maximum drawdown of 0.00%, a negative Sharpe ratio of -0.04, and high volatility of 36.78%. These metrics highlight the poor risk-adjusted returns and volatility associated with the investment.

CEO Commentary

Frank H. Laukien, Bruker’s President and CEO, acknowledged the challenging conditions in the US academic market, biopharma, and industrial sectors, all of which contributed to the second quarter's performance falling below expectations. He noted that while tariffs and currency headwinds have impacted the company, Bruker is taking action to mitigate these effects, including an expanded cost savings initiative. Laukien expressed cautious optimism about a potential partial demand recovery in FY 2026, citing the company’s historical resilience.

Guidance

Bruker has lowered its FY 2025 guidance, now expecting revenue in the range of $3.43 to $3.50 billion. This represents 2–4% year-over-year reported growth, with CER revenue remaining flat and organic revenue declining by the same range. Non-GAAP EPS is projected to fall between $1.95 and $2.05, compared to $2.41 in FY 2024. The company cited ongoing challenges in demand recovery, currency pressures, and mitigation efforts as factors behind the revised outlook. Bruker aims to improve visibility into academic funding trends, China stimulus, and biopharma research demand to support future performance.

Additional News

Bruker’s stock hit a 52-week low following a disappointing earnings report, with the share price falling to $32.27 during mid-day trading on Aug 6, 2025. The company reported a quarterly EPS of $0.32, missing the consensus estimate of $0.43 by $0.11, and revenue of $797.40 million, below the expected $811.17 million. In response, Bruker declared a quarterly dividend of $0.05 per share, which was paid on June 27 to shareholders of record on June 16, representing an annualized yield of 0.6%. Multiple analysts adjusted their price targets and ratings in the wake of the earnings miss, with Citigroup and Goldman Sachs lowering their outlook to “neutral,” while Bank of America and Jefferies maintained a “buy” stance. The average analyst rating remains “Hold” with a target price of $53.10. Additionally, CEO Frank H. Laukien purchased 2,608 shares in early June, signaling continued confidence in the company. Institutional ownership of the stock remains strong, with 79.52% held by hedge funds and other institutional investors.